2,6-Dibromomescaline

Last updated

2,6-Dibromomescaline
2,6-Dibromomescaline.svg
Clinical data
Other names2,6-DBM; 2,6-BM; DBM; DBR-M; DBr-M; Dibromomescaline; 2,6-Dibromo-3,4,5-trimethoxyphenethylamine
Routes of
administration 		Oral [1]
Drug class Serotonin receptor modulator; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Identifiers
  • 2-(2,6-dibromo-3,4,5-trimethoxyphenyl)ethanamine
PubChem CID
Chemical and physical data
Formula C11H15Br2NO3
Molar mass 369.053 g·mol−1
3D model (JSmol)
  • COC1=C(C(=C(C(=C1OC)Br)CCN)Br)OC
  • InChI=1S/C11H15Br2NO3/c1-15-9-7(12)6(4-5-14)8(13)10(16-2)11(9)17-3/h4-5,14H2,1-3H3
  • Key:SDKSMIRGLNJZJW-UHFFFAOYSA-N

2,6-Dibromomescaline (2,6-DBM or 2,6-BM), or dibromomescaline (DBM), also known as 2,6-dibromo-3,4,5-trimethoxyphenethylamine, is a psychedelic drug of the scaline family related to mescaline. [2] [3] [4] [1] It is the 2,6-dibromo derivative of mescaline and the 6-bromo derivative of 2-bromomescaline. [2] [1] The drug was first described in the scientific literature by Arthur Heffter in 1901 [2] [3] [5] and is said to have been on the recreational market since at least the 1990s. [1]

Contents

Use and effects

2,6-Dibromomescaline is described as having pronounced psychoactive effects but also toxicity, with this toxicity limiting its popularity and adoption as a recreational drug. [1] It is said to have doses of up to 50 mg orally. [1]

Interactions

Pharmacology

Pharmacodynamics

2,6-Dibromomescaline shows affinity for serotonin receptors, including the serotonin 5-HT1A, 5-HT2A, and 5-HT2C receptors (Ki = 22 nM, 149 nM, and 221 nM, respectively). [2] These affinities were 135-fold, 31-fold, and 35-fold higher than those of mescaline, respectively. [2] It was 3.4-fold more potent than mescaline in substituting for LSD in rodent drug discrimination tests. [2] [3]

Chemistry

Synthesis

The chemical synthesis of 2,6-dibromomescaline has been described. [3] [5]

Analogues

Analogues of 2,6-dibromomescaline include 2,6-dichloromescaline, 2,6-dimethylmescaline, 2-bromomescaline, 2-chloromescaline, 2-iodomescaline, and 2-methylmescaline, among others. [2]

History

2,6-Dibromomescaline was first described in the scientific literature by Arthur Heffter in 1901. [2] [3] [5] It was among the first synthetic psychedelic drugs to be described, although Heffter did not report its properties or effects in humans and those were not described until much later. [2] [5] [1] Subsequently, the drug was studied and described in greater detail by Matthew Aaron Parker of the lab of David E. Nichols at Purdue University in 1998. [2] [3] 2,6-Dibromomescaline is said to have been on the recreational market since at least the 1990s. [1]

See also

References

  1. 1 2 3 4 5 6 7 8 "2,6-BM (Dibromomescaline)". АИПСИН (in Russian). 1 May 1998. Retrieved 25 November 2025.
  2. 1 2 3 4 5 6 7 8 9 10 Trachsel D, Lehmann D, Enzensperger C (2013). Phenethylamine: von der Struktur zur Funktion [Phenethylamines: From Structure to Function]. Nachtschatten-Science (in German) (1 ed.). Solothurn: Nachtschatten-Verlag. pp. 934–936, 944. ISBN   978-3-03788-700-4. OCLC   858805226. Archived from the original on 21 August 2025.
  3. 1 2 3 4 5 6 Parker M (1998). Studies of perceptiotropic phenethylamines: Determinants of affinity for the 5-HT2A receptor (PhD. Thesis). Purdue University. Archived from the original on 2012-04-25. Retrieved 2011-12-16.
  4. ↑ Shulgin A, Manning T, Daley P (2011). The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds . Vol. 1. Berkeley: Transform Press. ISBN   978-0-9630096-3-0.
  5. 1 2 3 4 Heffter A (1901). "Ueber Cacteenalkaloide. (IV. Mittheilung)" [On cactus alkaloids. (IV. Communication)]. Berichte der deutschen chemischen Gesellschaft[Reports of the German Chemical Society] (in German). 34: 3004–3015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.